| P2093 | author name string | Kristi S Anseth | |
| | Chien-Chi Lin | |
| P2860 | cites work | Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation | Q28258318 |
| | A sensitivity study of the key parameters in the interfacial photopolymerization of poly(ethylene glycol) diacrylate upon porcine islets | Q30629118 |
| | Minireview: the glucagon-like peptides | Q31835814 |
| | N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. | Q33329455 |
| | In vitro and in vivo performance of porcine islets encapsulated in interfacially photopolymerized poly(ethylene glycol) diacrylate membranes. | Q33870613 |
| | Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice | Q33922982 |
| | Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus | Q34026346 |
| | Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes | Q34319292 |
| | Type 1 diabetes: new perspectives on disease pathogenesis and treatment | Q34321603 |
| | An encapsulation system for the immunoisolation of pancreatic islets | Q34420908 |
| | beta-Cell death during progression to diabetes | Q34462324 |
| | Biological actions and therapeutic potential of the glucagon-like peptides | Q34520645 |
| | The glucagon-like peptides: a double-edged therapeutic sword? | Q35181801 |
| | Alternative routes of insulin delivery | Q35591065 |
| | Closed-loop insulin delivery-the path to physiological glucose control | Q35637319 |
| | Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system | Q35714885 |
| | Hydrogels for oral delivery of therapeutic proteins | Q35790858 |
| | New sources of pancreatic beta-cells | Q36186494 |
| | The enhancement of chondrogenic differentiation of human mesenchymal stem cells by enzymatically regulated RGD functionalities | Q36593382 |
| | Is the oral route possible for peptide and protein drug delivery? | Q36601912 |
| | Challenges and emerging technologies in the immunoisolation of cells and tissues | Q37006047 |
| | Hydrogel encapsulation environments functionalized with extracellular matrix interactions increase islet insulin secretion | Q37073882 |
| | The effects of cell-matrix interactions on encapsulated beta-cell function within hydrogels functionalized with matrix-derived adhesive peptides | Q40153158 |
| | Alpha1-antitrypsin protects beta-cells from apoptosis | Q40158851 |
| | PEG-based hydrogels as an in vitro encapsulation platform for testing controlled beta-cell microenvironments | Q40279739 |
| | Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway | Q40663660 |
| | Cytokine-induced metabolic dysfunction of MIN6 beta cells is nitric oxide independent. | Q40764975 |
| | Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation | Q40778317 |
| | Long-term insulinotropic activity of glucagon-like peptide-1/polymer conjugate on islet microcapsules | Q42473757 |
| | Synthesis, bioactivity and specificity of glucagon-like peptide-1 (7-37)/polymer conjugate to isolated rat islets | Q45203500 |
| | Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity | Q45414510 |
| | Islet cell transplantation | Q45596753 |
| | Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1. | Q46589919 |
| | Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery | Q46851809 |
| | Enhanced protein delivery from photopolymerized hydrogels using a pseudospecific metal chelating ligand | Q46883116 |
| | PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice | Q46885178 |
| | Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation | Q46975451 |
| | Metal-chelating affinity hydrogels for sustained protein release. | Q50676220 |
| | Synthesis of immunoisolation barriers that provide localized immunosuppression for encapsulated pancreatic islets. | Q51162022 |
| | Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. | Q53864082 |
| | Treatment of type I diabetes using encapsulated islets | Q73850458 |
| | Incorporation of adhesion peptides into nonadhesive hydrogels useful for tissue resurfacing | Q74148784 |
| | Nicotinamide protects human beta cells against chemically-induced necrosis, but not against cytokine-induced apoptosis | Q74459259 |
| | Characterization of permeability and network structure of interfacially photopolymerized poly(ethylene glycol) diacrylate hydrogels | Q77163721 |
| | Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability | Q79283090 |
| | PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice | Q83061828 |
| P433 | issue | 9 | |
| P921 | main subject | hydrogel | Q898925 |
| P304 | page(s) | 2460-2467 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Biomacromolecules | Q1768006 |
| P1476 | title | Glucagon-like peptide-1 functionalized PEG hydrogels promote survival and function of encapsulated pancreatic beta-cells | |
| P478 | volume | 10 | |